Tvardi Therapeutics Inc., a clinical-stage biopharmaceutical company, has successfully completed its merger with Cara Therapeutics. As a result of the transaction, Tvardi received approximately $23.8 million in net cash from Cara, enhancing its financial position. This merger, combined with a previous private placement financing of $28.3 million, strengthens Tvardi's capability to fund its operations. The company now anticipates having sufficient resources to sustain its activities into the second half of 2026. The merger is expected to heighten Tvardi's visibility and access to capital, propelling its development programs, including those targeting idiopathic pulmonary fibrosis and hepatocellular carcinoma.